IBM

IBM, AMD, and ORNL launch a quantum-classical platform, but commercial impact is years away.

IBM renews US Open tech partnership as digital and broadcast engagement hit all-time highs.

IBM posts solid Q3 growth, raises free cash flow outlook, but debt and acquisition spend climb.

IBM Ventures invests in Leena AI, backing its AI automation for over 500 enterprises.

IBM advances to DARPA's Stage C for quantum computer validation; delivery targeted for 2029.

IBM showcases a 50% cycle time cut for clients using its new SAP Cloud ERP solution.

IBM’s US Open event is a brand showcase with no disclosed financial impact.

IBM closes HRL acquisition but discloses no financial or operational details.

IBM unveils a dual-architecture mainframe chip, but most benefits remain unproven.

IBM touts new AI features for US Open fans, but offers no financial details.

IBM’s quantum acquisition is bold but all upside is years away and unproven.

IBM posts solid profits but bets big on quantum with long-term, unproven upside.

IBM’s 24.6% share plunge signals deep investor concern after weak Q2 2026 results.

IBM touts new hardware, but offers no financials or near-term investment impact.

IBM’s chip breakthrough is real, but commercial payoff is years away and unproven.

IBM’s $5B AI security push is big on ambition, light on measurable results so far.

IBM touts digital wins at Wimbledon, but financial impact remains unproven and undisclosed.

IBM’s AI Builders Challenge is a marketing push, not a near-term investment catalyst.

IBM is betting big on quantum, but real payoffs are years away and far from certain.

IBM’s $5B AI security project is big on ambition, light on details and proof.

IBM’s quantum foundry plan is bold but mostly hype and years from proving itself.

IBM touts AI security leadership, but offers no hard numbers or proof of impact.

IBM's Saudi partnership is all promise, no proof—wait for real deals before acting.

IBM’s new software launch is all promise, with no financial or adoption proof yet.

IBM is selling big AI and quantum promises, but offers no hard business evidence yet.

IBM’s new MIT lab is long on ambition, short on near-term investor substance.

IBM touts growth but withholds numbers, leaving investors guessing about real progress.